SkinBioTherapeutics reports positive interim acne study findings

(Sharecast News) - Life science company SkinBioTherapeutics reported encouraging interim findings from its ongoing AxisBiotix acne food supplement study featuring its lead formulation on Tuesday. The AIM-traded firm said it intended to proceed with the study until completion, with final results expected before the end of the first quarter.

It said the volunteer study, comprising 220 participants, mirrored the methodology employed in the AxisBiotix-Ps study.

Participants were provided with the supplement containing the lead formulation in powder form, and were instructed to document their experiences via a dedicated app.

Evaluation criteria encompassed acne severity, pain levels, self-perception of appearance, and confidence levels.

The complete study duration would span 56 days, aligning with the skin's natural replenishment cycle.

That timeframe accounted for individual variations in skin regeneration, which typically ranges from 40 to 56 days, contingent on factors such as age and location.

"We are really excited to see such positive results against all the criteria at this interim stage," said chief executive officer Stuart Ashman.

"After the success of running a consumer participant study with the AxisBiotix-Ps product, we followed the same set-up for our acne candidate.

"And, just like the AxisBiotix study, many participants have recorded quite dramatic changes in their condition already.

"We have another three weeks to go, but if the final results reflect similar levels of effectiveness, we have the potential for a really important, new and effective option for people with acne of all ages."

At 1517 GMT, shares in SkinBioTherapeutics were down 1.54% at 9.6p.

Reporting by Josh White for Sharecast.com.